Phage-antibiotic synergism: A possible approach to combatting Pseudomonas aeruginosa

Research in Microbiology

Volumn 164, Issue 1, 2013, Pages 55-60

  Knezevic, Petar ^a   Curcin, Sanja ^b   Aleksic, Verica ^a   Petrusic, Milivoje ^a   Vlaski, Ljiljana ^c  

^a UNIVERSITY OF NOVI SAD   (Serbia)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF NOVI SAD   (Serbia)

Author keywords

Antibiotics; Bacteriophages; Pseudomonas aeruginosa; Synergism

Indexed keywords

ANTIBIOTIC AGENT; CEFTRIAXONE; CIPROFLOXACIN; GENTAMICIN; POLYMYXIN B;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL CELL; BACTERIAL COUNT; BACTERIAL GROWTH; BACTERIOPHAGE; CELL ELONGATION; CELL STRUCTURE; DRUG POTENTIATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

ANTI-BACTERIAL AGENTS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS PHAGES;

BACTERIA (MICROORGANISMS); PODOVIRIDAE; PSEUDOMONAS AERUGINOSA; SIPHOVIRIDAE;

EID: 84871718658     PISSN: 09232508     EISSN: 17697123     Source Type: Journal    
DOI: 10.1016/j.resmic.2012.08.008     Document Type: Article

References (32)

1. Adam D. Use of quinolones in pediatric patients. Rev. Infect. Dis. 1989, 11:1113-1116.
2. Bergogne-Berezin E. Antibacterial activity of ceftriaxone. Rev. Med. Interne. 1985, 6:178-186.
3. Comeau A.M., Tetart F., Trojet S.N., Prère M.F., Krisch H.M. Phage-antibiotic synergy (PAS): β-lactam and quinolone antibiotics stimulate virulent phage growth. PLoS One 2007, 2:e799.
4. Constantinou A., Voelker-Meiman K., Sternglanz R., McCorquodale M.M., McCorquodale J. Involvement of host DNA gyrase in growth of bacteriophage T5. J. Virol. 1986, 75:875-882.
5. De Wyngaert M.A., Hinkle D.C. Involvement of DNA gyrase in replication and transcrption of bacteriophage T7. J. Virol. 1979, 29:529-535.
6. Drago L., De Vechii E.D.E., Nicola L., Tocalli L., Gismondo M.R. Effect of moxifloxacin on bacterial pathogenicity factors in comparison with amoxicillin, clarithromycin and ceftriaxone. J. Chemother. 2004, 16:30-37.
7. Giamarellou H., Antoniadou A. Antipseudomonal antibiotics. Med. Clin. North. Am. 2001, 85:19-41.
8. Hagens S., Habel A., Blasi U. Augmentation of the antimicrobial efficacy of antibiotics by filamentous phage. Microb. Drug Resist. 2006, 12:164-168.
9. Hahn M.W., Moore E.R.B., Hofle M.B. Bacterial filament formation, a defense mechanism against flagellate grazing, is growth rate controlled in bacteria of different phyla. Appl. Environ. Microbiol. 1999, 65:25-35.
10. Hamatake R.K., Mukai R., Hayashi M. Role of DNA gyrase subunits in synthesis of bacteriophage F{cyrillic}X174 viral DNA. Proc. Natl. Acad. Sci. U S A 1981, 78:1532-1536.
11. Heo Y.-J., Lee Y.-R., Jung H.-H., Lee J., Ko G.G., Cho Y.-H. Antibacterial efficacy of phages towards Pseudomonas aeruginosa infections in mice and Drosophila melanogaster. Antimicrob. Agents Chemother. 2009, 53:2469-2474.
12. Himmelweit F. Combined action of penicillin and bacteriophage on Staphylococci. Lancet 1945, 246:104-105.
13. Hoiby N., Krogh J.H., Moser C., Song Z., Ciofu O., Kharazmi A. Pseudomonas aeruginosa and the in vitro and in vivo biofilm mode of growth. Microbes. Infect. 2001, 3:23-35.
14. Huff W.E., Huff G.R., Rath N.C., Balog J.M., Donoghue A.M. Therapeutic efficacy of bacteriophage and baytril (enrofloxacin) individually and in combination to treat colibacillosis in broilers. Poult. Sci. 2004, 83:1944-1947.
15. Kadurugamuwa J.L., Clarke A.J., Beveridge T.J. Surface action of gentamicin on Pseudomonas aeruginosa. J. Bacteriol. 1993, 175:5798-5805.
16. Knezevic P., Kostanjsek R., Obreht D., Petrovic O. Isolation of Pseudomonas aeruginosa specific bacteriophages with broad activity spectra. Curr. Microbiol. 2009, 59:173-180.
17. Knezevic P., Obreht D., Curcin S., Petrusic M., Aleksic V., Kostanjsek R., Petrovic O. Phages of Pseudomonas aeruginosa: response to environmental factors and in vitro ability to inhibit bacterial growth and biofilm formation. J. Appl. Microbiol. 2011, 111:245-254.
18. Livermore D.M. The need for new antibiotics. Clin. Microbiol. Infect. 2004, 10:1-9.
19. McKinnon P.S., Davis S.L. Pharmacokinetic and pharmacodynamic issues in the treatment of bacterial infectious diseases. Eur. J. Clin. Microbiol. Infect. Dis. 2004, 23:271-288.
20. McVay C.S., Velasquez M., Fralick J.A. Phage therapy of Pseudomonas aeruginosa infection in a mouse burn wound model. Antimicrob. Agents Chemother. 2007, 51:1934-1938.
21. Nordmann P., Naas T., Fortineau N., Poirel L. Superbugs in the coming new decade; multidrug resistance and prospects for treatment of Staphylococcus aureus, Enterococcus spp. and Pseudomonas aeruginosa in 2010. Curr. Opin. Microbiol. 2007, 10:436-440.
22. Perry T.R., Schentag J.J. Clinical use of ceftriaxone: a pharmacokinetic-pharmacodynamic perspective on the impact of minimum inhibitory concentration and serum protein binding. Clin. Pharm. 2001, 40:685-694.
23. Rahman M., Kuhn I., Rahman M., Olsson-Liljequist B., Möllby R. Evaluation of a scanner-assisted colorimetric MIC method for susceptibility testing of gram-negative fermentative bacteria. Appl. Environ. Microbiol. 2004, 70:2398-2403.
24. Rella M., Haas D. Resistance of Pseudomonas aeruginosa PAO to nalidixic acid and low levels of β lactam antibiotics: mapping of chromosomal genes. Antimicrob. Agents Chemother. 1982, 22:242-249.
25. Russell A.D. Types of antibiotics and synthetic antimicrobial agents. Pharmacelutical Microbiology 1998, 91-130. Blackwell Science Ltd. W.B. Hugo, A.D. Russell (Eds.).
26. Sambrook J., Russell D.W. Molecular Cloning: A Laboratory Manual 2001, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York. third ed.
27. Tam V.H., Schilling A.N., Vo G., Kabbara S., Kwa A.L., Wiederhold N.P., Lewis R.E. Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 2005, 49:3624-3630.
28. Verma P. Methods for determining bactericidal activity and antimicrobial interactions: synergy testing, time-kill curves, and population analysis. Antimicrobial Susceptibility Testing Protocols 2007, 275-299. CRC Press. R. Schwalbe, L. Steele-Moore, A.C. Goodwin (Eds.).
29. Wang J., Hu B., Xu M., Yan Q., Liu S., Zhu X., Sun Z., Reed E., Ding L., Gong J., Li Q.Q., Hu J. Use of bacteriophage in the treatment of experimental animal bacteremia from imipenem-resistant Pseudomonas aeruginosa. Int. J. Mol. Med. 2006, 17:309-317.
30. Watanabe R., Matsumoto T., Sano G., Ishii Y., Tateda K., Sumiyama Y., Uchiyama J., Sakurai S., Matsuzaki S., Imai S., Yamaguchi K. Efficacy of bacteriophages therapy against gut-derived sepsis caused by Pseudomonas aeruginosa in mice. Antimicrob. Agents Chemother. 2007, 51:446-452.
31. Wroblewska M. Novel therapies of multidrug-resistant Pseudomonas aeruginosa and Acinetobacter spp. Infections: State Art. Arch. Immunol. Ther. Ex. 2006, 54:113-120.
32. Zhao X., Xu C., Domagala J., Drlica K. DNA topoisomerse targets of the fluoroquinolones: a strategy for avoiding bacterial resistance. Proc. Natl. Acad. Sci. U S A 1997, 94:13991-13996.